Trial Profile
Post-marketing clinical study of rituximab monotherapy at eight weekly infusions in relapsed or refractory patients with indolent B-cell non-Hodgkin's lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2010
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Zenyaku Kogyo
- 15 Jan 2010 New trial record